Lowell Anthony is an Oncology physician affiliated with University of Kentucky. OpenAlex indexes 297 publications with 6,733 citations (h-index 38); ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Markey Cancer Ctr
800 Rose Street, Whitney Hedrickson Bldg
Lexington, KY 405360001
Telephone
859-323-6522Registry record last updated 15 May 2012.
Clinical trials
- Telotristat With Lutathera in Neuroendocrine Tumors
Sponsor: Lowell Anthony, MD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Exelixis Inc.Program year202514 payments
- HISTOSONICS, INC.Program year20251 payment
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
31.5%Kinase inhibitor25.4%Everolimus56%Cabometyx34%Sunitinib Malate10%Part D<11 patientsCytochrome P450 17A1 Inhibitor3.7%Abiraterone Acetate100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
27.6%Serotonin-3 Receptor Antagonist11%Ondansetron Hcl100%Part D≥26 patientsCorticosteroid7.1%Prednisone100%Part D≥15 patients+ 3 more classes in this area
Nervous system
26.6%Opioid Agonist12.8%Oxycodone Hcl100%Part D≥22 patientsBenzodiazepine8.5%Lorazepam62%Alprazolam38%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2018–2026 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
David Moliterno, MD
University of Kentucky
Robert Dipaola
University of Kentucky
Darwin Conwell, MD
University of Kentucky
Phillip Tibbs
University of Kentucky
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”